Scholarlink

<p>This study investigated blood selenium (Se) levels in chronic heart failure (CHF) patients and their correlation with cardiac function, followed by a meta-analysis of Se supplementation efficacy. We enrolled 191 CHF patients, measuring blood Se via 2,3-diaminonaphthalene fluorometry. Data were analyzed using SPSS 25.0 and GraphPad Prism 8.0. A systematic review of randomized trials on Se supplementation for CHF was conducted (RevMan 5.3 and Stata 16.0). CHF patients exhibited significantly lower blood Se (P<sub>2.5</sub>–P<sub>97.5</sub>: 55.12–81.38&#xa0;μg/L; median: 67.04&#xa0;μg/L) versus healthy controls. Lower Se levels correlated with obesity (<i>P</i> = 0.001), rural residence (<i>P</i> = 0.009), hypertension (<i>P</i> = 0.038), and advanced cardiac dysfunction (class III/IV vs. I/II, <i>P</i> = 0.002). Se inversely correlated with CRP (<i>r</i> =  − 0.22, <i>P</i> = 0.026). Meta-analysis revealed that Se supplementation reduced systolic blood pressure (<i>P</i> = 0.04) but increased LVESV (SMD = 0.21, <i>P</i> = 0.04). CHF patients frequently exhibit Se deficiency, linked to BMI, cardiac function, and inflammation. Hypertension and low Se may exacerbate cardiac dysfunction, while controlled Se supplementation could improve outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring the Impact of Selenium Supplementation on Nutritional, Inflammatory, and Cardiac Function in Chronic Heart Failure Patients: A Novel Approach to Managing Deficiency

  • 期刊论文

  • 发表日期：

    2025年7月16日

查看全文
  • Ladi Kou,
  • Fandong Meng,
  • Guotao Fu,
  • Rongqiang Zhang

摘要

This study investigated blood selenium (Se) levels in chronic heart failure (CHF) patients and their correlation with cardiac function, followed by a meta-analysis of Se supplementation efficacy. We enrolled 191 CHF patients, measuring blood Se via 2,3-diaminonaphthalene fluorometry. Data were analyzed using SPSS 25.0 and GraphPad Prism 8.0. A systematic review of randomized trials on Se supplementation for CHF was conducted (RevMan 5.3 and Stata 16.0). CHF patients exhibited significantly lower blood Se (P2.5–P97.5: 55.12–81.38 μg/L; median: 67.04 μg/L) versus healthy controls. Lower Se levels correlated with obesity (P = 0.001), rural residence (P = 0.009), hypertension (P = 0.038), and advanced cardiac dysfunction (class III/IV vs. I/II, P = 0.002). Se inversely correlated with CRP (r =  − 0.22, P = 0.026). Meta-analysis revealed that Se supplementation reduced systolic blood pressure (P = 0.04) but increased LVESV (SMD = 0.21, P = 0.04). CHF patients frequently exhibit Se deficiency, linked to BMI, cardiac function, and inflammation. Hypertension and low Se may exacerbate cardiac dysfunction, while controlled Se supplementation could improve outcomes.